ACUTE VIRAL HEPATITIS CLINICAL PRESENTATION DIGNOSIS EPEDEMOLOGY OF

  • Slides: 59
Download presentation
ACUTE VIRAL HEPATITIS • CLINICAL PRESENTATION. • DIGNOSIS. • EPEDEMOLOGY OF VIRAL HEPATITIS INFECTION

ACUTE VIRAL HEPATITIS • CLINICAL PRESENTATION. • DIGNOSIS. • EPEDEMOLOGY OF VIRAL HEPATITIS INFECTION A, B, C IN KSA. • MANAGEMENT.

Diagnosis of hepatitis Patient history Physical examination Liver function tests Serologic tests

Diagnosis of hepatitis Patient history Physical examination Liver function tests Serologic tests

Symptoms and Signs 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.

Symptoms and Signs 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. Pre-icteric phase Anorexia Fatigue Nausea Vomiting Arthralgia Myalgia Headache Photophobia Pharangitis

1. 2. 3. 4. 5. Icteric phase: : Enlarged liver Tender upper quadrant Discomfort

1. 2. 3. 4. 5. Icteric phase: : Enlarged liver Tender upper quadrant Discomfort Splenomegaly (10 -20%) General adenopathy Post-icteric phase

Lab Findings L FT increase >5 -10 times of normal 2. Markers of hepatitis

Lab Findings L FT increase >5 -10 times of normal 2. Markers of hepatitis B or C or A might be positive 1.

DD: Infectious Mononucleosis 2. Drug Induced Hepatitis 3. Chronic Hepatitis. 4. Alcohol Hepatitis 5.

DD: Infectious Mononucleosis 2. Drug Induced Hepatitis 3. Chronic Hepatitis. 4. Alcohol Hepatitis 5. Cholecystitis, Cholelithiasis 6 -Auto-immun hepatitis 1.

MARKERS OF VIRAL HEPATITIS HBV MARKERS HCV MARKERS HAV MARKERS

MARKERS OF VIRAL HEPATITIS HBV MARKERS HCV MARKERS HAV MARKERS

Hepatitis B Markers anti-HBc exposure (Ig. M = acute) HBs. Ag infection (carrier) anti-HBs

Hepatitis B Markers anti-HBc exposure (Ig. M = acute) HBs. Ag infection (carrier) anti-HBs immunity HBe. Ag viral replication anti-HBe seroconversion HBV-DNA viral replication:

Hepatitis C Markers ANTI -HCV PCR-RNA HCV

Hepatitis C Markers ANTI -HCV PCR-RNA HCV

Hepatitis A Markers HAV ig. M HAV ig. G

Hepatitis A Markers HAV ig. M HAV ig. G

Hepatitis E Markers HEV ig. M HEV ig. G HEV RNA PCR

Hepatitis E Markers HEV ig. M HEV ig. G HEV RNA PCR

AUTOIMMUN HEPATITIS MARKERS ANF ANTI MITOCHONDRIAL AB ANTI SMOOTH MUSCLES ABS.

AUTOIMMUN HEPATITIS MARKERS ANF ANTI MITOCHONDRIAL AB ANTI SMOOTH MUSCLES ABS.

AUTOIMMUN HEPATITIS MARKERS ANA) ANTI MITOCHONDRIAL ANTI SMOOTH MUSCLES ABS

AUTOIMMUN HEPATITIS MARKERS ANA) ANTI MITOCHONDRIAL ANTI SMOOTH MUSCLES ABS

INCIDENCE OF ACUTE HEPATITIS IN 5 HEPATOLOGY CLINICS IN KSA 2013 Causes of Hepatitis

INCIDENCE OF ACUTE HEPATITIS IN 5 HEPATOLOGY CLINICS IN KSA 2013 Causes of Hepatitis HAV HBV HCV AIH DILI KKUH 7 3 1 11 ? NGH 10 5 2 8 8 AMC 1 0 0 3 3 KFH 1 2 0 3 ? DAMMAM UN. 2 1 0 1 5 TOTAL 21 11 4 26 16

Complications 1. Chronic hepatitis 2. Fulmnant hepatitis cirrhosis- HCC

Complications 1. Chronic hepatitis 2. Fulmnant hepatitis cirrhosis- HCC

FULMINANT HEPATITIS Definition: Hepatic Failure Within 8 Weeks Of Onset Of Illness. Manifestation: Encephalopathy

FULMINANT HEPATITIS Definition: Hepatic Failure Within 8 Weeks Of Onset Of Illness. Manifestation: Encephalopathy and Prolonged PT Histopathology: Massive Hepatic Necrosis.

Natural History Gow, BMJ 2001

Natural History Gow, BMJ 2001

Possible transmission route of HBV in KSA 1 -Horisontal transmission (person to person) is

Possible transmission route of HBV in KSA 1 -Horisontal transmission (person to person) is the main transmission route 2 -Perintal transmission (positive HBSAG mothers) especially if they are HBEAG positive 3 - Heterosexual transmission 4 -Illegal injection drug use 5 - Contaminated equipment used for therapeutic injections and other health care related procedures 6 - Folk medicine practice 7 -Blood and blood products transfusion without prior screening

HBV INFECTION before and after vaccination program

HBV INFECTION before and after vaccination program

Positivity (%) OVERALL PREVALENCE OF HBs. Ag AMONG SAUDIS IN THE 80’S ACCORDING TO

Positivity (%) OVERALL PREVALENCE OF HBs. Ag AMONG SAUDIS IN THE 80’S ACCORDING TO REGIONS Al-Faleh. Annals of Saudi Medicine, 1988

PREVALENCE OF HBe. Ag AMONG HBs. Ag POSITIVE SAUDIS PREGNANT WOMEN (n = 20920)

PREVALENCE OF HBe. Ag AMONG HBs. Ag POSITIVE SAUDIS PREGNANT WOMEN (n = 20920) Al-Faleh, Annals of Saudi Medicine, 1988

FREQUENCY OF HBe. Ag AMONG HBs. Ag POSITIVE SAUDI CHILDREN (n=307) Al-Faleh et al.

FREQUENCY OF HBe. Ag AMONG HBs. Ag POSITIVE SAUDI CHILDREN (n=307) Al-Faleh et al. Journal of Infection, 1992

PREVENTION STRATEGIES OF MINISTRY OF HEALTH IN KSA Introducing HBV vaccine in EPI program;

PREVENTION STRATEGIES OF MINISTRY OF HEALTH IN KSA Introducing HBV vaccine in EPI program; and Mandatory screening of blood donors and expatriates. Vaccination of risk groups. Health education especially among medical personnel.

History of HBV infection control in KSA 1989 1990 Vaccination of All infants At

History of HBV infection control in KSA 1989 1990 Vaccination of All infants At birth Vaccination of all children at school entry 1990 until now vaccination of All risk groups mandatory 1990 until now Screening of all Expatriates coming To work in KSA

THE CURRENT EPI IN THE KINGDOM OF SAUDI ARABIA 1. 2. 3. 4. 5.

THE CURRENT EPI IN THE KINGDOM OF SAUDI ARABIA 1. 2. 3. 4. 5. 6. 7. 8. At birth At 6 weeks At 3 months At 5 months At 12 months At 18 months At 4 -6 years BCG + DPT 1 + OPV 1 DPT 2 + OPV 2 DPT 3 + OPV 3 Measles MMR (DPT + OPV) HB 1 Hb 2 HB 3 Booster 1 Booster 2

COMPARISON OF PREVALENCE OF HBs. Ag AMONG SAUDI CHILDREN IN 1989 (n=4575) AND 1997

COMPARISON OF PREVALENCE OF HBs. Ag AMONG SAUDI CHILDREN IN 1989 (n=4575) AND 1997 (n=5355) – ACCORDING TO AGE Al Faleh, J Infect 1999

COMPARISON OF PREVALENCE OF HBs. Ag AMONG SAUDI CHILDREN IN 1989 (n=4575) AND 1997

COMPARISON OF PREVALENCE OF HBs. Ag AMONG SAUDI CHILDREN IN 1989 (n=4575) AND 1997 (n=5355) – ACCORDING TO REGION Al Faleh, J Infect 1999

Prevalence Of HBs. Ag Among Saudi Population Before & After Vaccination over 18 y

Prevalence Of HBs. Ag Among Saudi Population Before & After Vaccination over 18 y Before After Age 1 -10 yr numbers 4575 1 -2 yr 637 1 -12 yr 3666 16 -18 yr 1365

Long Term Seroconversion Rate Over 18 Years (Anti-HBS) * ** *** Age N 1

Long Term Seroconversion Rate Over 18 Years (Anti-HBS) * ** *** Age N 1 -2 yr 637 1 -12 yr 3666 16 -18 yr 1365 * Al Faleh et al Annals of Saudi meds 1993 ** Al Faleh et al Journal of infection 1999 *** Al. Faleh et al journal of infection 2008

Long-Term protection of HB- vaccine over 18 years ( anti-HBS>10 IU/L)(n=1355) Age Region 1

Long-Term protection of HB- vaccine over 18 years ( anti-HBS>10 IU/L)(n=1355) Age Region 1 -2 yr 5 1 -8 yr 13 16 -18 yr 3 AL Faleh et al, J

CHANGING PATTERNS OF HBs. Ag POSITIVITY AMONG BLOOD DONORS IN MOH, CENTRAL BLOOD BANK

CHANGING PATTERNS OF HBs. Ag POSITIVITY AMONG BLOOD DONORS IN MOH, CENTRAL BLOOD BANK 1994 -2005

PREVALENCE OF HBs. Ag POSITIVITY AMONG BLOOD DONORS IN KKUH FROM 1987 TO 2008

PREVALENCE OF HBs. Ag POSITIVITY AMONG BLOOD DONORS IN KKUH FROM 1987 TO 2008

 ﻫـ 1435 -1429 ﻋﺪﺩ ﺣﺎﻻﺕ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺪ ﺏ ﻭﺝ NR. OF POSITIVE HBV&HCV

ﻫـ 1435 -1429 ﻋﺪﺩ ﺣﺎﻻﺕ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺪ ﺏ ﻭﺝ NR. OF POSITIVE HBV&HCV CASES(2009 -2014) HCV=RED 4174 4030 3735 3092 3049 3097 4500 4000 3500 2926 3000 2500 ﺍﻟﻜﺒﺪ ﺏ ﺍﻟﻜﺒﺪﺝ 616 678 704 706 2000 842 921 1500 1000 500 0 1435 h 1434 h 1433 h 1432 h 1431 h 1430 h 1429 h

Case report. 5/11/16 Ahmed is 16 Y/O student , living in TABUK, C/O abdominal

Case report. 5/11/16 Ahmed is 16 Y/O student , living in TABUK, C/O abdominal discomfort, nausea, Bloody diarrhea for 1 year. O/E : Lower abdominal pain His mother is positive for HBs. AG &HBe. AG.

Lab. results 12/11/16 : ALT 40/L(21 -72) AST 30 U/L (17 -59) ALKALINE PHOSPHATASE

Lab. results 12/11/16 : ALT 40/L(21 -72) AST 30 U/L (17 -59) ALKALINE PHOSPHATASE 80. 0 U/L. YGT 40, 0 U/L BIL. 1 MG/DL (0. 0 -1. 4) ALB. 4. 6 g/l(3. 5 -5. 0) INR (NORMAL)

Lab. results HBs. AG : POSITVE PCR QUANTITATIVE : 200 IU/ML

Lab. results HBs. AG : POSITVE PCR QUANTITATIVE : 200 IU/ML

Lab. results HBs. AG : POSITVE PCR QUANTITATIVE : 200 IU/ML

Lab. results HBs. AG : POSITVE PCR QUANTITATIVE : 200 IU/ML

FINAL DIAGNOSIS CARRIER OF VIRAL HEPATITS B

FINAL DIAGNOSIS CARRIER OF VIRAL HEPATITS B

Why this young boy is positive for hepatitis B? • He was not vaccinated

Why this young boy is positive for hepatitis B? • He was not vaccinated at birth? • He was vaccinated at birth, but did not • Completed the 3 doses ? • He was vaccinated at birth but did not • Received Hyperimmune globulin at birth? • He did not respond to the 3 doses of Vaccine ?

HCV INFECTION

HCV INFECTION

Natural history Marcellin, J Hepat 1999

Natural history Marcellin, J Hepat 1999

Overall prevalence rate of HCV infection in KSA among children and adolescent during the

Overall prevalence rate of HCV infection in KSA among children and adolescent during the last 18 yrs. 1989 1997 2008 No. of children Positive (%) 4496 39* (0. 87%) 5350 2** (0. 04%) Diagnostic test only by 1 st-generation EIA kit. Diagnostic test by 3 rd-generation EIA kit and confirmatory test by RIBA kit. * ALFaleh et al. Hepatology 1991 ** ALFaleh Ann Saudi Med. 2003 No. of students 1357 Positive (%) (5)3 0. 22% Diagnostic test by PCR for anti- HCV Positive cases.

Prevention Of HCV Transmission Avoiding shared use of Razors or brushes and any item

Prevention Of HCV Transmission Avoiding shared use of Razors or brushes and any item that pierces the skin. Strict adherence of the universal precautions in health facilities. Educating and training of HCW’s to the proper use of standard precautions Folk medicine? !

HAV INFECTION

HAV INFECTION

COMPARISON OF PREVALENCE OF ANTI-HAV AMONG SAUDI CHILDREN IN 1989 (n=4375) AND 1997 (n=5255)

COMPARISON OF PREVALENCE OF ANTI-HAV AMONG SAUDI CHILDREN IN 1989 (n=4375) AND 1997 (n=5255) – ACCORDING TO AGE Al-Faleh et al. Saudi Med. J, 1999

COMPARISON OF PREVALENCE OF ANTI-HAV AMONG SAUDI CHILDREN IN 1989 (n=4375) AND 1997 (n=5255)

COMPARISON OF PREVALENCE OF ANTI-HAV AMONG SAUDI CHILDREN IN 1989 (n=4375) AND 1997 (n=5255) – ACCORDING TO REGION

Changing pattern of Hepatitis A prevalence within the Saudi population over 18 yrs *

Changing pattern of Hepatitis A prevalence within the Saudi population over 18 yrs * * * Age Regio n 1 -10 YRS 13 1 -12 yrs 13 *** 16 -18 yrs 3 *Al. Rashed R. Ann SM 1997 ** Al. Faleh et al SMJ 1999 *** Al. Faleh et al WJG 2008

THANK YOU

THANK YOU